These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 24475542)

  • 41. Your business in court and at Federal agencies: 2011-2012.
    Reiss JB; Crowder D; McCabe B; DeFeo M; Rifin M; Talbot M
    Food Drug Law J; 2013; 68(1):1-51, i. PubMed ID: 24640636
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health.
    Gostin LO
    JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642
    [No Abstract]   [Full Text] [Related]  

  • 43. Tort claims and federal regulation of medical devices vs pharmaceuticals.
    Green M
    JAMA; 2009 Sep; 302(11):1169; author reply 1169-70. PubMed ID: 19755694
    [No Abstract]   [Full Text] [Related]  

  • 44. Risk, responsibility, and generic drugs.
    Kesselheim AS; Avorn J; Greene JA
    N Engl J Med; 2012 Nov; 367(18):1679-81. PubMed ID: 23113477
    [No Abstract]   [Full Text] [Related]  

  • 45. Access to safety data--stockholders versus prescribers.
    Pfeffer MA; Bowler MB
    N Engl J Med; 2011 Jul; 365(1):1-3. PubMed ID: 21714642
    [No Abstract]   [Full Text] [Related]  

  • 46. Greater and lesser powers of tort reform: the primary jurisdiction doctrine and state-law claims concerning FDA-approved products.
    Struve CT
    Cornell Law Rev; 2008 Jul; 93(5):1039-74. PubMed ID: 18618970
    [No Abstract]   [Full Text] [Related]  

  • 47. Prescription drugs, products liability, and preemption of tort litigation.
    DeAngelis CD; Fontanarosa PB
    JAMA; 2008 Oct; 300(16):1939-41. PubMed ID: 18940985
    [No Abstract]   [Full Text] [Related]  

  • 48. Iron-containing supplements and drugs; label warning statements and unit-dose packaging requirements; removal of regulations for unit-dose packaging requirements for dietary supplements and drugs. Final rule; removal of regulatory provisions in response to court order.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Oct; 68(201):59714-5. PubMed ID: 14567392
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Administrative "health courts" for medical injury claims: the federal constitutional issues.
    Elliott ED; Narayan SA; Nasmith MS
    J Health Polit Policy Law; 2008 Aug; 33(4):761-98. PubMed ID: 18617674
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is tobacco a drug? Administrative agencies as common law courts.
    Sunstein CR
    Duke Law J; 1998 Apr; 47(6):1013-69. PubMed ID: 10557544
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmaceuticals and medical devices: FDA oversight.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-28. PubMed ID: 19297718
    [No Abstract]   [Full Text] [Related]  

  • 52. The "natural" aversion: the FDA's reluctance to define a leading food-industry marketing claim, and the pressing need for a workable rule.
    Farris AL
    Food Drug Law J; 2010; 65(2):403-24, iv. PubMed ID: 24475548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Post-decision diagnosis: medical device preemption alive and mostly well after Medtronic, Inc. v. Lohr.
    Sayler SW; Thomas SM
    Ann Health Law; 1997; 6():185-208. PubMed ID: 10184786
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Judicial developments in the US Hatch-Waxman infringement safe harbor.
    Swirnoff AH; Becker DM
    Expert Opin Ther Pat; 2010 Apr; 20(4):451-8. PubMed ID: 20302449
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Law & psychiatry: SSRIs, suicide, and liability for failure to warn of medication risks.
    Appelbaum PS
    Psychiatr Serv; 2011 Apr; 62(4):347-9. PubMed ID: 21459983
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Teva v. Eisai: what's the real "controversy"?
    Wang GL
    Food Drug Law J; 2011; 66(4):631-54, iii. PubMed ID: 24505831
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The National Childhood Vaccine Injury Act and the supreme court's interpretation.
    Blake V
    Virtual Mentor; 2012 Jan; 14(1):31-4. PubMed ID: 23116914
    [No Abstract]   [Full Text] [Related]  

  • 58. Warning label limbo. FDA rule letting generic-drug makers update risk alerts draws heavy flak.
    Carlson J
    Mod Healthc; 2014 Jun; 44(26):20-2. PubMed ID: 25134408
    [No Abstract]   [Full Text] [Related]  

  • 59. How Much Information is Enough? Understanding the Alabama Supreme Court's Expansion of the Causation Standard in Failure to Warn Claims.
    Herr A
    Am J Law Med; 2023 Mar; 49(1):128-133. PubMed ID: 37376912
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Implied preemption of state tort law claims against prescription drug manufacturers based upon FDA approval.
    Blair WW
    J Leg Med; 2006 Sep; 27(3):289-303. PubMed ID: 16959653
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.